Why C-Rad stock moves
C-Rad rose clearly without company news.
Written after the close on ·
Why today
16,292 news analyzed todayC-Rad rose clearly without company news.
Over the last five trading days it rose clearly, while the market was roughly flat.
That is a big move for C-Rad, roughly twice a normal five-day stretch, and similar moves happened about ten times in the past year.
An order from a US medical centre worth about SEK 8 million was announced earlier last week, and it is a plausible background factor.
Next, C-Rad reports its earnings on Thursday 11 February 2027.
Today's move of +2.13% was 1.8 times a normal day's 1.2%. OMX Stockholm 30 moved −1.01% on the same day.
C-Rad +2.13%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for C-Rad.
C-Rad earned more than expected in 3 out of 8 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 7 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 24.00 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 0.32 SEK (February 11). For the current fiscal year, expected earnings per share changed from 2.28 SEK three months ago to 1.98 SEK now. 2026 estimate: 1.98 SEK. 2027 estimate: 1.96 SEK. One analyst made these estimates. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. October 26: Buy about 250 thousand SEK. August 11: Buy about 71 thousand SEK. August 10: Sell about 71 thousand SEK. July 31: Buy about 73 thousand SEK. July 30: Sell about 73 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +7% and earnings per share went from 1.67 SEK to 0.31 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 789 m SEKRevenue 2025: 442 m SEK
What the key figures say about C-Rad
The figures connect what C-Rad earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: 0.22 SEK–1.67 SEK. Peers: Microbot Medical -$0.25, Episurf Medical -0.07 SEK, Sedana Medical -0.35 SEK. 2026 estimate: 1.98 SEK (1.98 SEK–1.98 SEK). 2027 estimate: 1.96 SEK (1.96 SEK–1.96 SEK).
What the company sold during the year.
2022–2025: 301 m SEK–469 m SEK. Peers: Microbot Medical $0.3M, Episurf Medical 26.1 m SEK, Sedana Medical 198 m SEK. 2026 estimate: 414 m SEK (414 m SEK–414 m SEK). 2027 estimate: 455 m SEK (455 m SEK–455 m SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: 7.2%–15.0%. Peers: Microbot Medical −5348.8%, Episurf Medical −428.1%, Sedana Medical −17.9%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: 3.0%–17.4%. Peers: Microbot Medical −32.9%, Episurf Medical −91.1%, Sedana Medical −3.9%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 18.0–173.2. 2026 estimate: 12.1. 2027 estimate: 12.2.
What investors pay for each unit the company sells.
2022–2025: 2.15–4.27. Peers: Microbot Medical 215.47, Episurf Medical 34.62, Sedana Medical 4.77. 2026 estimate: 1.91. 2027 estimate: 1.74.
The ordinary yearly dividend as a percentage of the share price.
2022–2025: 0.0%–0.0%. Peers: Microbot Medical 0.0%, Episurf Medical 0.0%, Sedana Medical 0.0%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -5.97–-1.58.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 3.06–5.30. Peers: Microbot Medical 1.08, Episurf Medical 0.65, Sedana Medical 1.08.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 10.8–53.6.
Cash left after investments, divided by the number of shares.
2022–2025: -0.05 SEK–1.51 SEK. Peers: Microbot Medical -$0.27, Episurf Medical -0.00 SEK, Sedana Medical -0.70 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 66.4%–71.5%.
The dividend explained
A dividend is money paid to shareholders. C-Rad paid 0.10 SEK per share in the twelve months through November 6, 2026.
On the ex-dividend day, May 8, 2026, C-Rad traded without the right to the 0.10 SEK dividend. The price went from 32.90 SEK to 33.70 SEK; including the dividend, the day's change was +2.7%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2026 so far: 0.10 SEK
What to watch next, and why
The earnings report shows how C-Rad's revenue and profit have changed.
- Earnings report
The earnings report shows how C-Rad's revenue and profit have changed.
Add to calendar
More about C-Rad
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Thomas Axelsson, chairBuyabout 250 thousand SEK
- Linda Maria Elisabet Eixmann Frölén, CFOBuyabout 71 thousand SEK
- Linda Maria Elisabet Eixmann Frölén, CFOSellabout 71 thousand SEK
- Linda Maria Elisabet Eixmann Frölén, CFOBuyabout 73 thousand SEK
- Linda Maria Elisabet Eixmann Frölén, CFOSellabout 73 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 16 report days C-Rad usually moved about 3.5%. On a normal day it moves 1.2%.
−23.34% Why? +4.75% +23.05% −10.16%
10,000 SEK in C-Rad bought on November 7, 2016 is worth 22,000 SEK today, with dividends reinvested.
What would 10,000 SEK in C-Rad be worth today? →
What would 10,000 SEK in C-Rad be worth today?
22,000 SEK
with dividends reinvested, bought on November 7, 2016.
The five biggest days of the journey
· −23.3% · the whole market fell 2.5% the same day · report day · Why?
· +23.0% · the whole market rose 2.8% the same day · report day
· +22.6% · the whole market fell 0.1% the same day
· +20.8% · the whole market fell 0.2% the same day · report day
· −15.8% · the whole market rose 0.4% the same day · report day
Earlier days
+3.45% market −0.11% C-Rad rose clearly over the week, while the broader market was roughly flat. Read →
C-Rad rose clearly over the week, while the broader market was roughly flat.
The move was big for the stock, about twice a normal five-day stretch.
Moves that size happened only about ten times in the past year.
That is before this week, so it works as background rather than a new trigger.
−1.26% market −0.32% C-Rad fell, more than the market, which slipped slightly. Read →
C-Rad fell, more than the market, which slipped slightly.
No company news explains the drop.
Shares traded at about twice their usual volume.
The move was within C-Rad's usual daily range.
Over the last five trading days, C-Rad rose slightly, while the market also rose slightly.
+0.00% market +0.83% C-Rad roughly flat; no company news explains it. Read →
C-Rad roughly flat; no company news explains it.
C-Rad rose very sharply over the last five trading days, while OMX Stockholm 30 rose slightly.
That is a very big move, about five times a normal five-day stretch for the stock.
Moves this big happened about five times in the past year.
The biggest driver was likely the US order worth about SEK 8 million, announced earlier in the week, which strengthened its position in the US radiation therapy market.
+1.28% market −0.08% C-Rad rose clearly without a company-news explanation. Read →
C-Rad rose clearly without a company-news explanation.
Over the same day OMX Stockholm 30 was roughly flat, so C-Rad moved on its own.
Over the last five trading days the shares rose very sharply, far more than the market's slight gain.
The rise came after an US order worth about SEK 8 million was announced last week.
The move in the last session was not tied to new company news.
+1.29% market +0.48% C-Rad rose over the last 5 trading days. Read →
C-Rad rose over the last 5 trading days.
The last session's rise was ordinary for C-Rad, and no company news explains the move that day.
Over the same five days, the sector's median move was slightly positive, and the market rose clearly.
Earlier this period, C-Rad won an order worth about SEK 8 million from a US medical centre, which likely drew buyers in.
The next earnings report is due on 11 February 2027.
+0.00% market −0.29% C-Rad was roughly unchanged, an ordinary day. Read →
C-Rad was roughly unchanged, an ordinary day.
Over the same days the wider market fell slightly, so C-Rad held up better.
No company news from that session explains the move.
Over the last five trading days, C-Rad rose very sharply, far more than the market, which rose clearly.
That rebound follows a weak quarterly report last week, after which the shares fell sharply and then recovered.
+10.48% market +3.01% C-Rad rose very sharply over the week, a very big move for the company. Read →
C-Rad rose very sharply over the week, a very big move for the company.
The market, OMX Stockholm 30, also rose clearly, but C-Rad moved more than the index.
On Wednesday, C-Rad won an order worth about SEK 8 million from a large US medical centre, which likely supported the shares.
Trading was well above normal, and the shares remain well below their high of the past year.
+7.91% market +0.41% C-Rad rose, well ahead of a market that rose slightly. Read →
C-Rad rose, well ahead of a market that rose slightly.
No company news from that session explains the move.
Over the last five trading days it rose sharply, in line with the market.
The buyback, the US order and the upbeat service revenue point were announced earlier, so they are background rather than the trigger.
A strong move on heavy trading like this is rare for C-Rad.
−4.55% market +0.41% C-Rad fell very sharply, moving against the market. Read →
C-Rad fell very sharply, moving against the market.
Results were weak: quarterly revenue and orders fell and operating profit roughly halved.
Pareto Securities cut its price target, the share price it sees as fair, to SEK 35 from SEK 42 while keeping a buy rating.
The announced buyback of up to SEK 20 million was not enough to offset the disappointment.
The stock trades near its lowest close of the past year, and the move was very large compared with its usual daily swings.
−26.32% market −3.67% C-Rad fell very sharply over the last five trading days, moving much more than the Stockholm market, which also fell sharply. Read →
C-Rad fell very sharply over the last five trading days, moving much more than the Stockholm market, which also fell sharply.
The main driver was the weak third-quarter report published yesterday: revenue dropped about a quarter and operating profit (EBIT, earnings before interest and tax) roughly halved, as product deliveries fell in Europe and Asia.
Analysts such as Pareto Securities cut their fair-value estimate but kept a buy rating.
The company also launched a share buyback of up to SEK 20 million, which likely limited the decline.
−23.34% market −2.51% C-Rad fell very sharply, moving far more than the market. Read →
C-Rad fell very sharply, moving far more than the market.
Over the same day, OMX Stockholm 30 fell sharply, so C-Rad's drop was much steeper than the index.
The main driver was its quarterly report, published that day, which showed weaker sales and orders.
Order intake (new orders booked) fell 29 percent, and revenue fell 24 percent, both driven mainly by weaker sales in Europe, the Middle East and Africa.
Operating profit (EBIT) roughly halved, to MSEK 10 from 21, though a high share of service revenue (steady maintenance income) supported margins.
Learn more · Why do stocks go up and down?